Danyelza Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to poor outcomes in relapsed neuroblastoma, advances in monoclonal antibody therapy, orphan drug approvals, pediatric oncology specialization, clinical success of gd2 targeting.

The growth in the forecast period can be attributed to growth in pediatric cancer trials, expansion of immuno oncology pipelines, increased access to specialty cancer centers, supportive reimbursement policies, rising awareness of rare cancers. Major trends in the forecast period include growing adoption of targeted immunotherapy, rising use of gd2 directed treatments, expansion of pediatric oncology therapies, increased combination cancer treatment approaches, focus on refractory and relapsed cancers.

The rising prevalence of pediatric cancers is anticipated to drive the growth of the Danyelza market in the coming years. Pediatric cancers are those that occur in children and adolescents, encompassing types such as leukemia, brain tumors, neuroblastoma, and lymphomas. The increasing prevalence of these cancers is linked to factors including advancements in diagnostic methods, environmental exposures, genetic predispositions, and long-term effects of cancer treatments. Danyelza (naxitamab) is a targeted immunotherapy that helps address pediatric cancers by effectively treating high-risk neuroblastoma. Its use alongside other therapies has demonstrated improved survival rates and reduced disease progression in children with this aggressive cancer. For example, in October 2024, the Cancer Council, an Australia-based non-profit organization, reported that in 2022 approximately 93 children aged 0-14 years in Australia died from cancer. Additionally, there were 206 cancer diagnoses in children under 15 and 263 in those aged 15-24 in Victoria. By 2023, there were 6,197 males and 5,523 females alive who had been diagnosed with cancer during childhood or adolescence. Therefore, the rising prevalence of pediatric cancers is contributing to the growth of the Danyelza market.

Key companies in the Danyelza market are focusing on developing innovative treatments, such as targeted immunotherapies, to expand therapeutic options and improve patient outcomes. Targeted immunotherapy refers to treatments that use substances to specifically target and attack cancer cells by recognizing proteins or markers, such as GD2 in neuroblastoma, allowing the immune system to destroy malignant cells. For instance, in May 2023, Y-mAbs Therapeutics Inc., a US-based biotechnology company, obtained marketing authorization from Brazil’s Agência Nacional de Vigilância Sanitária for Danyelza (naxitamab-gqgk) 40 mg/10 mL injection, indicated for high-risk neuroblastoma. Danyelza is a recombinant humanized monoclonal antibody that targets GD2, a ganglioside common in neuroectoderm-derived tumors and sarcomas, and was developed by Memorial Sloan Kettering Cancer Center under an exclusive license to Y-mAbs.

In November 2024, Nobelpharma Co., Ltd., a Japan-based pharmaceutical company specializing in curative drugs and medical devices, partnered with Y-mAbs Therapeutics Inc. Under the agreement, Nobelpharma will manage the development, regulatory submission, and marketing of Danyelza in Japan, including sales and distribution, if approved. Y-mAbs Therapeutics Inc. is a US-based biotech firm specializing in cancer immunotherapies, including danyelza.

Major companies operating in the danyelza market are Y-mAbs Therapeutics Inc.

North America was the largest region in the danyelza market in 2025. The regions covered in the danyelza market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the danyelza market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have influenced the danyelza market by raising costs for biologic manufacturing inputs, cold chain logistics, and specialized oncology packaging. These impacts are more pronounced in regions reliant on imported monoclonal antibodies such as asia pacific. Treatment costs in specialty cancer centers have increased. However, tariffs have supported regional biologics manufacturing partnerships. This enhances long term access to pediatric oncology therapies.

The danyelza market research report is one of a series of new reports that provides danyelza market statistics, including danyelza industry global market size, regional shares, competitors with a danyelza market share, detailed danyelza market segments, market trends and opportunities, and any further data you may need to thrive in the danyelza industry. This danyelza market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Danyelza, also known as naxitamab, is a monoclonal antibody combined with granulocyte-macrophage colony-stimulating factor (GM-CSF) to treat certain high-risk cancers. It is primarily approved for pediatric patients aged 1 year and older, as well as adults with relapsed or refractory high-risk neuroblastoma involving the bone or bone marrow, especially when previous treatments achieved only partial or stable responses. Danyelza targets GD2, a protein commonly found on neuroblastoma cells, allowing the immune system to attack these cancerous cells effectively.

The main indications for danyelza include neuroblastoma, osteosarcoma, and other GD2-positive cancers. Neuroblastoma is a cancer that develops in nerve cells, most commonly affecting children, and the use of Danyelza for neuroblastoma is expanding as more pediatric cancer therapies are approved. Treatment approaches include monotherapy and combination therapy, with distribution to hospitals, specialty clinics, and cancer and radiation therapy centers.

The danyelza market consists of sales of genetically modified donor pancreas cells, cell transplantation, and immune suppression drugs. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.